The Day In Review: Affymax, Inc. Stages Strong IPO

Published: Dec 15, 2006

December 15, 2006 -- With only two weeks left in 2006, Affymax staged the most successful biotech IPO of the entire year; Immunicon reported its breast cancer test was accepted by the FDA; Luminex bought fellow genetic testing company Tm Bioscience; Elan and Biogen Idec asked the FDA to approve Tysabri for Crohn’s disease; Medtronic began testing its Valiant Stent for thoracic aortic aneurysms; Genta received another Not Approvable ruling for Genasense; OSI and Roche received a positive recommendation in Europe for Tarceva as an adjunct to Gemzar; Critical Therapeutics began a trial to see if Zyflo can shorten hospital stays for COPD patients; and ImmunoGen pointed to a study showing positive results for a drug that uses its Tumor-Activated Prodrug technology. The Centient Biotech 200™ climbed 13 points to 3964, a rise of .34%. More details...

Back to news